Documents & Downloads

Elpamotide

Neovascular Inhibitor

Elpamotide is an epitope peptide that targets VEGFR2, functioning as a neovascular inhibitor. It induces cytotoxic T lymphocytes (CTLs) to selectively eliminate VEGFR2-expressing endothelial cells, demonstrating potential immunostimulatory and antineoplastic properties. Elpamotide is applicable in cancer research, including studies focused on pancreatic cancer.

Out of Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer	Adooq Bioscience
Actions	Inhibitor
CAS Number	673478-49-4
Applications	Neovascular Inhibitor
Formula	C₄₇H₇₆N₁₆O₁₃
Molecular Weight	1073.21
SMILES	C([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@H](CCCNC(=N)N)N)=O)=O)[C@@H](C)C)(=O)N2[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@@H]([C@H](CC)C)C(O)=O)=O)CCCNC(=N)N)=O)CC(N)=O)=O)=O)CC(O)=O)=O)CCC2

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.